Cargando…

Current Therapeutic Options in the Treatment of Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of the joints. Untreated RA leads to a destruction of joints through the erosion of cartilage and bone. The loss of physical function is the consequence. Early treatment is important to control disease a...

Descripción completa

Detalles Bibliográficos
Autores principales: Köhler, Birgit M., Günther, Janine, Kaudewitz, Dorothee, Lorenz, Hanns-Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678427/
https://www.ncbi.nlm.nih.gov/pubmed/31261785
http://dx.doi.org/10.3390/jcm8070938
_version_ 1783441098391158784
author Köhler, Birgit M.
Günther, Janine
Kaudewitz, Dorothee
Lorenz, Hanns-Martin
author_facet Köhler, Birgit M.
Günther, Janine
Kaudewitz, Dorothee
Lorenz, Hanns-Martin
author_sort Köhler, Birgit M.
collection PubMed
description Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of the joints. Untreated RA leads to a destruction of joints through the erosion of cartilage and bone. The loss of physical function is the consequence. Early treatment is important to control disease activity and to prevent joint destruction. Nowadays, different classes of drugs with different modes of action are available to control the inflammation and to achieve remission. In this review, we want to discuss differences and similarities of these different drugs.
format Online
Article
Text
id pubmed-6678427
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66784272019-08-19 Current Therapeutic Options in the Treatment of Rheumatoid Arthritis Köhler, Birgit M. Günther, Janine Kaudewitz, Dorothee Lorenz, Hanns-Martin J Clin Med Review Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of the joints. Untreated RA leads to a destruction of joints through the erosion of cartilage and bone. The loss of physical function is the consequence. Early treatment is important to control disease activity and to prevent joint destruction. Nowadays, different classes of drugs with different modes of action are available to control the inflammation and to achieve remission. In this review, we want to discuss differences and similarities of these different drugs. MDPI 2019-06-28 /pmc/articles/PMC6678427/ /pubmed/31261785 http://dx.doi.org/10.3390/jcm8070938 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Köhler, Birgit M.
Günther, Janine
Kaudewitz, Dorothee
Lorenz, Hanns-Martin
Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
title Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
title_full Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
title_fullStr Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
title_full_unstemmed Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
title_short Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
title_sort current therapeutic options in the treatment of rheumatoid arthritis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678427/
https://www.ncbi.nlm.nih.gov/pubmed/31261785
http://dx.doi.org/10.3390/jcm8070938
work_keys_str_mv AT kohlerbirgitm currenttherapeuticoptionsinthetreatmentofrheumatoidarthritis
AT guntherjanine currenttherapeuticoptionsinthetreatmentofrheumatoidarthritis
AT kaudewitzdorothee currenttherapeuticoptionsinthetreatmentofrheumatoidarthritis
AT lorenzhannsmartin currenttherapeuticoptionsinthetreatmentofrheumatoidarthritis